Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Conducting Oncology Clinical Trials in Africa II: Regulatory Process for...

Mr Dennis Ake, MSc.

Conducting Oncology Clinical Trials in Africa II: Regulatory Process for Clinical Trials in Africa ( Mr Dennis Ake, MSc. )

Early safety from a trial of talimogene laherparepvec (T-VEC) injected into...

Prof J. Randy Hecht - UCLA Jonsson Comprehensive Cancer Center, Santa Monica...

Early safety from a trial of talimogene laherparepvec (T-VEC) injected into liver tumours plus pembrolizumab ( Prof J. Randy Hecht - UCLA Jonsson Comprehensive Cancer Center, Santa Monica, USA )

CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer

Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA

CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer ( Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA )

Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma

Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA

$Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma ( Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA )$

Conducting Oncology Clinical Trials in Africa II: Twitter Workshop

Runcie C.W. Chidebe - Executive Director, Project PINK BLUE

Conducting Oncology Clinical Trials in Africa II: Twitter Workshop ( Runcie C.W. Chidebe - Executive Director, Project PINK BLUE )

Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin...

Dr John Kuruvilla - Princess Margaret Cancer Centre, Toronto, Canada

$Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin lymphoma ( Dr John Kuruvilla - Princess Margaret Cancer Centre, Toronto, Canada )$

FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO...

Prof Robert Huddart and Dr Ignacio Durán

FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO 2020 ( Prof Robert Huddart and Dr Ignacio Durán )

Perioperative chemotherapy with mFOLFIRINOX vs gemcitabine/nab-paclitaxel for...

Prof Davendra Sohal - University of Cincinnati, Cincinnati, USA

Perioperative chemotherapy with mFOLFIRINOX vs gemcitabine/nab-paclitaxel for resectable pancreatic ductal adenocarcinoma ( Prof Davendra Sohal - University of Cincinnati, Cincinnati, USA )

High-dose twice daily thoracic radiotherapy in limited disease small-cell lung...

Prof Bjørn Henning Grønberg - Trondheim University Hospital, Trondheim, Norway

High-dose twice daily thoracic radiotherapy in limited disease small-cell lung cancer ( Prof Bjørn Henning Grønberg - Trondheim University Hospital, Trondheim, Norway )

ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for...

Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia

ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients with Waldenström macroglobulinemia ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )

Background of the KEYLYNK-007 trial for advanced solid tumours

Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA

Background of the KEYLYNK-007 trial for advanced solid tumours ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )

US MM-6: Long-term proteasome inhibition in multiple myeloma following an in...

Dr Sudhir Manda - Arizona Oncology / US Oncology Research, Tucson, USA

US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib ( Dr Sudhir Manda - Arizona Oncology / US Oncology Research, Tucson, USA )

More from ecancer